D.E. Shaw & Co
FPRX

D.E. Shaw & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

D.E. Shaw & Co’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-350,212
Closed -$1.65M – 4278
2020
Q3 		$1.65M Sell
350,212
-17,575
-5% -$89.3K ﹤0.01% 2526
2020
Q2 		$2.24M Buy
367,787
+114,890
+45% +$473K ﹤0.01% 2327
2020
Q1 		$575K Sell
252,897
-33,199
-12% -$141K ﹤0.01% 3138
2019
Q4 		$1.31M Buy
286,096
+93,402
+48% +$370K ﹤0.01% 2791
2019
Q3 		$747K Buy
192,694
+106,048
+122% +$582K ﹤0.01% 2998
2019
Q2 		$522K Buy
86,646
+71,703
+480% +$686K ﹤0.01% 3056
2019
Q1 		$200K Sell
14,943
-100
-0.7% -$1.14K ﹤0.01% 3406
2018
Q4 		$140K Buy
+15,043
New +$179K ﹤0.01% 3604
2018
Q3 		– Sell
-15,157
Closed -$240K – 4075
2018
Q2 		$240K Buy
+15,157
New +$264K ﹤0.01% 3477
2018
Q1 		– Sell
-21,913
Closed -$480K – 3885
2017
Q4 		$480K Buy
21,913
+1,467
+7% +$47.2K ﹤0.01% 3002
2017
Q3 		$837K Buy
20,446
+1,978
+11% +$62.1K ﹤0.01% 2602
2017
Q2 		$556K Sell
18,468
-1,393
-7% -$43.5K ﹤0.01% 2765
2017
Q1 		$718K Sell
19,861
-25,331
-56% -$1.12M ﹤0.01% 2532
2016
Q4 		$2.26M Sell
45,192
-42,723
-49% -$2.24M ﹤0.01% 1904
2016
Q3 		$4.62M Buy
87,915
+15,716
+22% +$750K 0.01% 1345
2016
Q2 		$2.98M Sell
72,199
-101,624
-58% -$4.42M 0.01% 1634
2016
Q1 		$7.06M Sell
173,823
-89,195
-34% -$3.07M 0.01% 1058
2015
Q4 		$10.9M Buy
263,018
+206,628
+366% +$6.93M 0.02% 933
2015
Q3 		$868K Sell
56,390
-146,369
-72% -$3.15M ﹤0.01% 2697
2015
Q2 		$5.04M Sell
202,759
-56,390
-22% -$1.26M 0.01% 1460
2015
Q1 		$5.92M Buy
259,149
+189,409
+272% +$4.78M 0.01% 1269
2014
Q4 		$1.88M Buy
+69,740
New +$1.2M ﹤0.01% 2330

Other funds holding FPRX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's FPRX Position: Q4 2020 in Review

D.E. Shaw & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2020, closing a stake of 350,212 shares — an estimated $1.65M sold.

D.E. Shaw & Co first reported a position in FPRX in Q4 2014 and held it in 22 quarters. The position peaked at $10.9M in Q4 2015. 125 funds tracked by Wall St. Rank hold FPRX as of Q4 2020.

  • D.E. Shaw & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • D.E. Shaw & Co sold 350,212 Five Prime Therapeutics, Inc. shares in Q4 2020, an estimated $1.65M.
  • D.E. Shaw & Co first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
  • D.E. Shaw & Co's Five Prime Therapeutics, Inc. position peaked at $10.9M in Q4 2015.
  • 125 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2020.

Based on D.E. Shaw & Co's 13F filing for Q4 2020, filed 16 Feb 2021.